N@N

Bacterin International Holdings, Inc. Schedules Third Quarter 2012 Financial Earnings Conference Call

^{Published on 2012-10-23 13:46:15 - Market Wire}
 

Bacterin International Holdings, Inc. Schedules Third Quarter 2012 Financial Earnings Conference Call -- BELGRADE, Mont., Oct. 23, 2012 /PRNewswire/ --

BELGRADE, Mont., Oct. 23, 2012 /PRNewswire/ -- [ Bacterin International Holdings ], Inc. (NYSE Amex: [ BONE ]), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will release its financial results for the three and 9 months ended September 30, 2012 after the close of regular market trading on Wednesday, November 7, 2012. A conference call will follow at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: [ BONE ]) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit [ www.bacterin.com ].

Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
INVESTOR INQUIRIES:
Hayden IR
James Carbonara, Regional Vice President, 646-755-7412
[ james@haydenir.com
Brett ] Maas, 646-536-7331
[ brett@haydenir.com ]

SOURCE Bacterin International, Inc.